Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly NNC0195-0092 vs daily Norditropin in growth hormone–naïve pre-pubertal children with growth hormone deficiency
2015-000531-32Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of somapacitan in growth hormone deficiency (GHD) (2 arms), sponsored by Novo Nordisk. Started Nov 2015; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2015-000531-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000531-32.